1. World Health Organisation. The safety of medicines in public 
health programmes: Pharmacovigilance an essential tool. 
The Uppsala Monitoring; 2006. www.who.int/medicines/
areas/quality_safety_efficacy/pharmacovigilance_B.pdf
[Last accessed on 2015 Apr 15].
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, 
Walley TJ, et al. Adverse drug reactions as cause of admission 
to hospital: Prospective analysis of 18 820 patients. BMJ 
2004;329:15‑9.
3. Ye X, Fu Z, Wang H, Du W, Wang R, Sun Y, et al. Acomputerized 
system for signal detection in spontaneous reporting system of 
Shanghai China. Pharmacoepidemiol Drug Saf 2009;18:154‑8.
4. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of 
adverse drug reaction related admissions according to method 
of detection, admission urgency and medical department 
specialty. BMC Clin Pharmacol 2009;9:8.
5. Oshikoya KA, Chukwura H, Njokanma OF, Senbanjo IO, Ojo I. 
Incidence and cost estimate of treating pediatric adverse drug 
reactions in Lagos, Nigeria. Sao Paulo Med J 2011;129:153‑64.
6. Inman WH. Attitudes to adverse drug reaction reporting. Br 
J Clin Pharmacol 1996;41:434‑5.
7. Hajebi G, Mortazavi SA, Salamzadeh J, Zian A. A survey 
of knowledge, attitude and practice of nurses towards 
pharamacovigilance in Taleqani hospital. Iran J Pharm Res 
2010;9:199‑206.
8. Desai CK, Iyer G, Panchal J, Shah S, Dikshit RK. An evaluation 
of knowledge, attitude, and practice of adverse drug reaction 
reporting among prescribers at a tertiary care hospital. 
Perspect Clin Res 2011;2:129‑36.
9. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, 
Aronson JK, et al. Adverse drug reactions in a hospital general 
medical unit meriting notification to the Committee on Safety 
of Medicines. Br J Clin Pharmacol 1996;42:423‑9